United States Biotechnology & Medical Research

Cabaletta Bio Inc (CABA)

Track

The most recent insider trading activity at Cabaletta Bio Inc occurred on January 21, 2026. On this date, multiple executives and insiders, including the CEO and Chief Medical Officer, executed significant open-market purchases of company shares. There have been no reported insider transactions since that date, which is more than three months ago.
Ticker: CABA Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Cabaletta Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 21 Jan 2026
Value US$463,524.60 | Price 31.09 | Shares 31,698 (+34.7%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-21 2026-01-21 B Purchase
4.0
Simon Mark
Non-Executive Director
31,698 +34.7%
31.09
US$463,525 		31,698 +34.7% 31.09 US$463,525
2026-01-21 2026-01-21 B Purchase
3.3
Chang David J.

Chief Medical Officer

Officer
61,573 +0.6%
333.54
US$3,373,800 		61,573 +0.6% 333.54 US$3,373,800
2026-01-21 2026-01-21 B Purchase
4.0
Binder Gwendolyn

President, Science & Tech.

Officer
36,097 -42.5%
315.77
US$963,707 		36,097 -42.5% 315.77 US$963,707
2026-01-21 2026-01-21 B Purchase
3.3
Gerard Michael

General Counsel

Officer
6,600 +inf%
2.27
US$14,979 		6,600 +inf% 2.27 US$14,979
2026-01-21 2026-01-21 B Purchase
3.3
Gavel Steve

Chief Commercial Officer

Officer
22,170 +inf%
2.27
US$50,215 		22,170 +inf% 2.27 US$50,215
2026-01-21 2026-01-21 B Purchase
3.7
Tomasello Shawn
Non-Executive Director
22,725 +inf%
2.21
US$50,322 		22,725 +inf% 2.21 US$50,322
2026-01-21 2026-01-21 B Purchase
4.0
Nichtberger Steven

President & CEO

Executive Director
45,000 +4.6%
2.24
US$100,778 		45,000 +4.6% 2.24 US$100,778
2026-01-21 2026-01-21 B Purchase
4.0
Bollard Catherine
Non-Executive Director
4,405 +440.5%
2.27
US$9,982 		4,405 +440.5% 2.27 US$9,982
2024-01-19 2024-01-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
700 -3.4%
20.33
US$14,229 		700 -3.4% 20.33 US$14,229
2024-01-19 2024-01-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
10,300 -33.2%
19.54
US$201,210 		10,300 -33.2% 19.54 US$201,210
2023-12-19 2023-12-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
3,132 -13.5%
22.22
US$69,593 		3,132 -13.5% 22.22 US$69,593
2023-12-19 2023-12-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
7,868 -25.4%
21.76
US$171,196 		7,868 -25.4% 21.76 US$171,196
2023-11-21 2023-11-20 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
7,458 -27.2%
18.02
US$134,405 		7,458 -27.2% 18.02 US$134,405
2023-11-21 2023-11-20 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
3,542 -11.4%
17.39
US$61,608 		3,542 -11.4% 17.39 US$61,608
2023-11-20 2023-11-20 PrS Proposed sale
4.0
GWENDOLYN BINDER

Officer

Officer
33,000
17.96
US$592,680 		33,000 17.96 US$592,680
2023-10-19 2023-10-19 PrS Proposed sale
4.0
GWENDOLYN BINDER

Officer

Officer
11,000
13.46
US$148,005 		11,000 13.46 US$148,005
2023-10-19 2023-10-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
408 -2.0%
14.28
US$5,825 		408 -2.0% 14.28 US$5,825
2023-10-19 2023-10-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
10,592 -34.2%
13.32
US$141,096 		10,592 -34.2% 13.32 US$141,096
2023-09-20 2023-09-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
700 -3.4%
18.50
US$12,950 		700 -3.4% 18.50 US$12,950
2023-09-20 2023-09-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
10,300 -33.2%
17.50
US$180,270 		10,300 -33.2% 17.50 US$180,270
2023-09-19 2023-09-19 PrS Proposed sale
4.0
GWENDOLYN BINDER

Officer

Officer
11,000
18.65
US$205,150 		11,000 18.65 US$205,150
2023-08-22 2023-08-21 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
300 -1.5%
13.82
US$4,147 		300 -1.5% 13.82 US$4,147
2023-08-22 2023-08-21 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
10,700 -34.5%
13.41
US$143,436 		10,700 -34.5% 13.41 US$143,436
2023-08-21 2023-08-21 PrS Proposed sale
4.0
GWENDOLYN BINDER

Officer

Officer
11,000
12.68
US$139,480 		11,000 12.68 US$139,480
2023-07-19 2023-07-19 PrS Proposed sale
4.0
GWENDOLYN BINDER

Officer

Officer
11,000
13.98
US$153,780 		11,000 13.98 US$153,780
2023-07-19 2023-07-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
2,815 -12.3%
14.26
US$40,143 		2,815 -12.3% 14.26 US$40,143
2023-07-19 2023-07-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
8,185 -26.4%
13.67
US$111,879 		8,185 -26.4% 13.67 US$111,879
2023-06-21 2023-06-20 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
11,000 -35.5%
12.99
US$142,925 		11,000 -35.5% 12.99 US$142,925
2023-06-20 2023-06-20 PrS Proposed sale
4.0
GWENDOLYN BINDER

Officer

Officer
11,000
13.12
US$144,320 		11,000 13.12 US$144,320
2023-06-20 2023-06-20 PrS Proposed sale
4.0
GWENDOLYN BINDER

Officer

Officer
11,000
13.12
US$144,320 		11,000 13.12 US$144,320
2023-05-19 2023-05-19 PrS Proposed sale
4.0
GWENDOLYN BINDER

Officer

Officer
22,000
12.30
US$270,600 		22,000 12.30 US$270,600
2023-05-19 2023-05-19 PlS Planned sale
4.0
Binder Gwendolyn

See Remarks

Officer
22,000 -52.4%
11.81
US$259,833 		22,000 -52.4% 11.81 US$259,833
2022-10-19 2022-10-19 B Purchase
4.0
Nichtberger Steven

President & CEO

Executive Director
8,127 +0.8%
1.25
US$10,152 		8,127 +0.8% 1.25 US$10,152
2022-10-18 2022-10-18 B Purchase
4.0
Simon Mark
Non-Executive Director
7,000 +inf%
0.98
US$6,835 		7,000 +inf% 0.98 US$6,835
2022-10-18 2022-10-18 B Purchase
4.0
Simon Mark
Non-Executive Director
118,000 +650.4%
0.98
US$115,286 		118,000 +650.4% 0.98 US$115,286
2022-10-18 2022-10-18 B Purchase
4.0
Bollard Catherine
Non-Executive Director
1,000 +inf%
0.99
US$994 		1,000 +inf% 0.99 US$994
2022-10-18 2022-10-18 B Purchase
4.0
Binder Gwendolyn

See Remarks

Officer
20,000 +inf%
0.99
US$19,894 		20,000 +inf% 0.99 US$19,894
2022-10-18 2022-10-18 B Purchase
3.4
Marda Anup

Chief Financial Officer

Officer
50,000 +inf%
0.99
US$49,620 		50,000 +inf% 0.99 US$49,620
2022-10-18 2022-10-18 B Purchase
4.0
Nichtberger Steven

President & CEO

Executive Director
141,873 +17.0%
0.99
US$141,008 		141,873 +17.0% 0.99 US$141,008
2021-11-03 2021-11-01 S Sale
3.5
5AM Ventures V, L.P.
Large shareholder
36,544 -9.9%
13.00
US$475,072 		36,544 -9.9% 13.00 US$475,072
2021-11-03 2021-11-01 S Sale
3.5
5AM Ventures V, L.P.
Large shareholder
258,456 -13.0%
13.00
US$3,359,928 		258,456 -13.0% 13.00 US$3,359,928
2021-01-12 2021-01-12 S Sale
3.5
5AM Ventures V, L.P.
Large shareholder
10,530 -2.8%
13.00
US$136,890 		10,530 -2.8% 13.00 US$136,890
2021-01-12 2021-01-12 S Sale
3.5
5AM Ventures V, L.P.
Large shareholder
74,470 -2.8%
13.00
US$968,110 		74,470 -2.8% 13.00 US$968,110
2021-01-12 2021-01-08 S Sale
3.5
5AM Ventures V, L.P.
Large shareholder
37,411 -9.0%
13.00
US$486,343 		37,411 -9.0% 13.00 US$486,343
2021-01-12 2021-01-08 S Sale
3.5
5AM Ventures V, L.P.
Large shareholder
264,589 -9.0%
13.00
US$3,439,657 		264,589 -9.0% 13.00 US$3,439,657
2020-12-14 2020-12-10 S Sale
3.5
5AM Ventures V, L.P.
Large shareholder
36,916 -8.1%
14.75
US$544,511 		36,916 -8.1% 14.75 US$544,511
2020-12-14 2020-12-10 S Sale
3.5
5AM Ventures V, L.P.
Large shareholder
261,084 -8.1%
14.75
US$3,850,989 		261,084 -8.1% 14.75 US$3,850,989
2019-10-31 2019-10-29 B Purchase
3.5
5AM Ventures V, L.P.
Large shareholder
454,545 +inf%
11.00
US$4,999,995 		454,545 +inf% 11.00 US$4,999,995
2019-10-30 2019-10-29 B Purchase
2.8
Flynn James E
Large shareholder
700,000 +inf%
11.00
US$7,700,000 		700,000 +inf% 11.00 US$7,700,000
Explore more

More insider trading research around Cabaletta Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America